CimCure

CimCure was founded in 2015 by its CSO, Prof. Arjan Griffioen, who is a world-renowned expert in angiogenesis, the process of blood vessel formation. CimCure is a spin-off company of Amsterdam UMC, one of the largest academic medical centers in the Netherlands. CimCure has a strong scientific team with extensive experience in immunology, pharmacology, and oncology.

CimCure's lead product is CimVax-001, a conjugate vaccine that consists of a tumor vascular antigen (TVA) linked to a carrier protein. CimVax-001 has shown promising results in preclinical studies, demonstrating potent anti-tumor and anti-metastatic effects in various animal models. CimVax-001 is currently in phase I clinical trials in patients with advanced solid tumors.

CimCure has also developed a platform technology that allows the rapid identification and validation of novel TVAs for different types of cancer. This technology enables CimCure to create a pipeline of customized cancer vaccines for various indications and patient populations.

CimCure has received several awards and grants for its innovative technology and product development. In 2018, CimCure won the prestigious Amsterdam Science & Innovation Award for its breakthrough approach to cancer immunotherapy. In 2019, CimCure received a €2.5 million grant from the European Union's Horizon 2020 program to support the clinical development of CimVax-001.

Foundation: 2015
Headquarters: Amsterdam, Netherlands
Website: https://cimcure.com/